Pasireotide Acetate

SKU: orb1296348

Description

Pasireotide Acetate

Research Area

Pharmacology & Drug Discovery

Key Properties

• CAS Number: 396091-76-2
• MW: 1107.26
• Purity: 99.87%
• Formula: C₆₀H₇₀N₁₀O₁₁
• SMILES: CC(O)=O.NCCCC[C@@H]1NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@@H](NC(=O)[C@@H]2C[C@H](CN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(OCc3ccccc3)cc2)NC1=O)OC(=O)NCCN)c1ccccc1
• Target: Somatostatin
• Solubility: DMSO:50 mg/mL (45.16 mM)

Bioactivity

• In Vivo:
  METHODS: Pasireotide (SOM230) acetate (160 mg/kg, subcutaneous injection, four months) was administered to a MEN1 transgenic mouse model, and the effects of Pasireotide (SOM230) acetate on insulin secretion, glucose levels, tumor growth and survival were tested. RESULTS Pasireotide (SOM230) acetate significantly decreased serum insulin, increased serum glucose, decreased tumor size and increased Pdx1-Cre cell apoptosis.
• In Vitro:
  Pasireotide (SOM230) acetate enhances agonist activity at growth inhibitory receptors with pKi of 8.2, 9.0, 9.1, less than 7.0 and 9.9 for sst1, 2, 3, 4 and 5, respectively.

Storage & Handling

• Storage: store at low temperature,keep away from moisture,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

antiproliferative, antisecretory, Pasireotide, Pasireotide Acetate, Inhibitor, inhibit, Somatostatin Receptor, somatostatin, SOM 230, SOM230, SOM-230, sst2, sst1, sst3, sst4, sst5, SSTR, SSTRs, proapoptotic

Compound Identifiers

PubChem CID

72205932